ZIOPHARM Oncology is a biopharmaceutical company focused on the discovery and development of new cancer therapies. The Company's technology platform employs Intrexon Corporation's RheoSwitch Therapeutic System to turn on and off and precisely modulate gene expression at the cancer site in order to improve the therapeutic index. ZIOPHARM is applying the latest technologies in cancer research to develop safer, more precise therapeutics to improve care and quality of life for patients.
Type
Public
HQ
Boston, US
Founded
2005
Size (employees)
36 (est)
ZIOPHARM Oncology was founded in 2005 and is headquartered in Boston, US
Report incorrect company information

Key People/Management at ZIOPHARM Oncology

Laurence Cooper

Laurence Cooper

CEO
David Mauney

David Mauney

CBO and COO
Francois Lebel

Francois Lebel

EVP, Research & Development, Chief Medical Officer

ZIOPHARM Oncology Office Locations

ZIOPHARM Oncology has an office in Boston
Boston, US (HQ)
1 First Avenue Parris Building, #34
Show all (1)
Report incorrect company information

ZIOPHARM Oncology Financials and Metrics

ZIOPHARM Oncology Financials

ZIOPHARM Oncology's revenue was reported to be $6.86 m in FY, 2016 which is a 58.4% increase from the previous period.
USD

Net income (FY, 2017)

(54.3 m)

EBIT (FY, 2017)

(53.5 m)

Market capitalization (18-Apr-2018)

617.8 m

Cash (31-Dec-2017)

70.9 m
ZIOPHARM Oncology's current market capitalization is $617.8 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

800 k1.4 m4.3 m6.9 m

Revenue growth, %

72%216%58%

General and administrative expense

14.4 m14.8 m

R&D expense

157.8 m45.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

General and administrative expense

3.1 m3.4 m3 m2.8 m4.3 m7.1 m3.1 m3.8 m3.7 m3.5 m3.6 m3.8 m

R&D expense

12 m10.8 m

Operating expense total

9.3 m10 m11.4 m12.6 m78.5 m14.5 m20 m14 m132.9 m12.5 m15.6 m14.6 m14.7 m

EBIT

(9.1 m)(9.8 m)(11.2 m)(11.9 m)(78.2 m)(14.2 m)(18.2 m)(12 m)(131.2 m)(10.9 m)(14 m)(13 m)(13.1 m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

68.2 m42.8 m140.7 m81.1 m70.9 m

Accounts Receivable

508.4 m19 k

Inventories

1.9 m1.1 m11.4 m23.8 m

Current Assets

70.3 m44.1 m152.5 m104.9 m90.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

23.6 m60.4 m53 m46.1 m129.7 m118.6 m163.8 m124.8 m109 m94.7 m66.4 m97.2 m84.4 m

Inventories

30.5 m

Current Assets

27.3 m62 m54 m47.8 m130.6 m123.1 m172.5 m140.4 m126.7 m115.7 m92.8 m125.1 m114.9 m

PP&E

1.3 m679 k683 k654 k426 k321 k262 k667 k682 k825 k1.1 m1.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(57.1 m)(31.8 m)(120.1 m)(165.3 m)(54.3 m)

Depreciation and Amortization

738 k462 k357 k290 k369 k

Inventories

5 m809 k(10 m)(12 m)

Accounts Payable

(1.1 m)1.6 m4 k(1.9 m)4.3 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(48.2 m)(9.7 m)(15.3 m)(21.4 m)(78.2 m)(92.4 m)(110.6 m)(12 m)(143.2 m)(154.1 m)(15.5 m)(28.3 m)(12.7 m)

Depreciation and Amortization

582 k124 k217 k339 k122 k236 k295 k72 k155 k227 k79 k167 k

Inventories

30.5 m

Accounts Payable

(618 k)156 k25 k1.5 m(1.2 m)1.1 m2.2 m(100 k)23 k(194 k)70 k(75 k)1.5 m
USDY, 2017

Financial Leverage

-1.1 x
Show all financial metrics
Report incorrect company information